NCT03892096: Development and Validation of a qPCR Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

NCT03892096
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients with HR++ disease must express ER+; Patients with tumors that are ER++/HER2-neg must have progressed on hormone therapy within the last two years
Exclusions: 
https://ClinicalTrials.gov/show/NCT03892096

Comments are closed.

Up ↑